| | Start your project at an advantage What’s the optimal Hit ID approach to enable success? Check out our advanced HTS system and shape diverse lead-like library, matched with knowledge-based, fragment and big data virtual screening options. |
Today's Rundown Sanofi C-suite explains Regeneron deal 'simplification,' ramping up its pipeline After Dravet hiccup, Zogenix's Fintepla prevails in phase 3 Lennox-Gastaut test Diffusion CSO and co-founder Gainer set to resign next month Another Takeda/Shire R&D exec jumps ship as Pharvaris nabs Peng Lu as its new CMO Chiesi creates Boston rare disease unit ahead of Fabry launch GenapSys raises $75M to bring its tabletop DNA sequencer to Asia amid coronavirus outbreak How blocking a 'first responder' in blood vessels could prevent heart disease EuroBiotech Report—Sanofi's MS data, Roche in SMA, MaaT, GeNeuro and GSK FiercePharmaAsia—Remdesivir patent in coronavirus; Takeda plant sale; Glenmark spinoff hire Chutes & Ladders—Aerie taps former Allergan exec as new VP Featured Story | | | Friday, February 7, 2020 It’s been a busy year for Sanofi: It’s been rejigging deals with the likes of Regeneron and bought out a biotech in the form of Synthorx. |
|
|---|
|
Top Stories Friday, February 7, 2020 After a rocky ride, Zogenix’s Fintepla turned up encouraging phase 3 data in a second type of rare childhood epilepsy. The drug beat placebo at cutting seizure frequency for patients with Lennox-Gastaut syndrome who typically experience dozens of seizures each month. In addition, more patients taking Fintepla saw their monthly seizures reduce by half than patients on placebo. Friday, February 7, 2020 Diffusion Pharmaceuticals’ co-founder and chief scientific officer John Gainer is set to leave the drug development company. Gainer invented the trans bipolar carotenoid family of molecules worked on by Diffusion but is now planning to leave the company next month. Friday, February 7, 2020 After getting off a $66 million series B in September last year, hereditary angioedema (HAE) specialist Pharvaris has taken on a seasoned HAE developer to help lead its pipeline. Friday, February 7, 2020 Chiesi Farmaceutici has set up a rare disease unit in Boston. The division will develop treatments for patients with rare lysosomal storage, hematological and ophthalmological disorders. Thursday, February 6, 2020 Just months after collecting $90 million to support the launch of its compact DNA sequencing hardware, GenapSys has raised another $75 million to finance its global expansion with its eyes set on the Asia-Pacific market and the expanding coronavirus outbreak. Thursday, February 6, 2020 A research team led by the University of Oxford has discovered a molecular “first responder” in endothelial cells that detects blood-flow stress. Targeting the shape of this force detector could reduce harmful plaques in arteries and therefore holds promise for preventing serious heart diseases, they argue. Thursday, February 6, 2020 In this week's EuroBiotech Report, Sanofi hits goal in phase 2 MS trial, Roche posts pivotal SMA data and MaaT bags €18 million for microbiome trials. Friday, February 7, 2020 The ongoing coronavirus outbreak in China has triggered a weird patent case around Gilead's remdesivir. Takeda is looking to sell a Shire biologics plant, and it doesn't expect U.S. Natpara supply for another year. Glenmark's biotech spinoff Ichnos hired Novartis exec as its chief development officer. And more. Friday, February 7, 2020 Aerie nabs former Allergan exec Senchnya as VP of medical affairs; Novartis' Basson takes CMO role at Boston; Hannah tapped as CMO at CytomX. Resources Sponsored by: Medidata To conduct a successful trial, do you need to understand the global eConsent Regulatory landscape? Sponsored by: Veeva Learn how data management teams at ICON, Bioforum, and Vertex Pharmaceuticals are creating the spec and casebook in a single step, reducing study build times and effort by over 50%. Sponsored by: Quotient Sciences Tufts Center for the Study of Drug Development (CSDD) white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug, compared to traditional multi-vendor development paradigms. Sponsored by: Catalent Get expert insights on strategies to implement flexible manufacturing and different technologies that are easily scalable and reproducible. Sponsored by: Catalent Regardless of the assigned FDA expedited approval designation and approach, the key action items should be: the assurance of a detail-oriented plan and the adaption of a “forward-thinking” approach that will assist in any future challenges and opportunities for growth of each project. Sponsored by: Catalent Learn how recent innovations in demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric. Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. 11th Annual SCOPE Summit: Summit for Clinical Ops Executives February 18-21, 2020 | Orlando, FL BioBasics 101: The Biology of Biotech March 26-27, 2020 | Boston, MA BioBasics 101: The Biology of Biotech April 16-17, 2020 | Philadelphia, PA Drug Development Immersion April 23-24, 2020 | Boston, MA BIO International Convention June 8-11, 2020 | San Diego, CA Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now and begin Pre-Boot Camp Preparation. | Take your new medicine development skills to the next level. | 